HC Wainwright Has Negative Estimate for MCRB FY2026 Earnings

Seres Therapeutics, Inc. (NASDAQ:MCRB) – Research analysts at HC Wainwright dropped their FY2026 earnings estimates for Seres Therapeutics in a research report issued on Wednesday, November 4th. HC Wainwright analyst M. Keller now expects that the biotechnology company will post earnings per share of ($6.78) for the year, down from their previous estimate of ($6.33). The consensus estimate for Seres Therapeutics’ current full-year earnings is ($6.33) per share. HC Wainwright also issued estimates for Seres Therapeutics’ Q4 2026 earnings at ($1.56) EPS, FY2027 earnings at ($1.77) EPS and FY2028 earnings at ($1.87) EPS.

Other analysts have also issued reports about the stock. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 18th. Wall Street Zen raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $17.00.

Seres Therapeutics Price Performance

Shares of Seres Therapeutics stock opened at $2.09 on Friday. Seres Therapeutics has a fifty-two week low of $1.67 and a fifty-two week high of $29.98. The firm has a fifty day moving average price of $3.40 and a two-hundred day moving average price of $6.91.

Seres Therapeutics (NASDAQ:MCRB) last announced its earnings results on Wednesday, November 4th. The biotechnology company reported ($1.63) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.63). The company had revenue of $0.59 million for the quarter, compared to the consensus estimate of $6.35 million. Seres Therapeutics had a negative return on equity of 175.40% and a negative net margin of 2,209.55%.

Institutional Trading of Seres Therapeutics

An institutional investor recently bought a new position in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new position in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. 59.34% of the stock is owned by hedge funds and other institutional investors.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.